Abstract
It has been well recognized that inflammatory responses are part of pathogenesis for various disorders such as autoimmune diseases. For example, multiple sclerosis (MS) is an inflammatory demyelinating disease of central nervous system that is presumably caused by activated T cells specific for myelin antigens. Rheumatoid arthritis (RA) is also a chronic inflammatory disease characterized by synovial inflammation in which several inflammatory cytokines are involved. On the other hand, Osteopontin (Opn) is a pleiotropic cytokine expressed by activated T cells, dendritic cells (DCs) and macrophages and its expression is up-regulated during inflammation. Secreted form of Opn (s-Opn), which is modified by phosphorylation, glycosylation and proteolytic cleavage with thrombin, has activities as a T helper type 1 (Th1) cytokine and as a chemoattractant for many types of cells through integrin receptors and CD44. Recently, it has been uncovered that intracellular form of Opn (i-Opn) is a critical regulator for Toll like receptor-9 (TLR-9), TLR-7- dependent interferon-α (IFN-α) expression by plasmacytoid DCs and Th17 development. In this review, we have summarized recent progress in understanding of Opns role in variety of inflammatory disorders.
Keywords: Autoimmune disease, Secreted form of Opn, Intracellular form of Opn, Thrombin cleaved form of Opn, Alpha4 integrin, Apha9 integrin, Plasmacytoid DC, Conventional DC
Current Drug Targets
Title: Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Volume: 11 Issue: 4
Author(s): Junko Morimoto, Shigeyuki Kon, Yutaka Matsui and Toshimitsu Uede
Affiliation:
Keywords: Autoimmune disease, Secreted form of Opn, Intracellular form of Opn, Thrombin cleaved form of Opn, Alpha4 integrin, Apha9 integrin, Plasmacytoid DC, Conventional DC
Abstract: It has been well recognized that inflammatory responses are part of pathogenesis for various disorders such as autoimmune diseases. For example, multiple sclerosis (MS) is an inflammatory demyelinating disease of central nervous system that is presumably caused by activated T cells specific for myelin antigens. Rheumatoid arthritis (RA) is also a chronic inflammatory disease characterized by synovial inflammation in which several inflammatory cytokines are involved. On the other hand, Osteopontin (Opn) is a pleiotropic cytokine expressed by activated T cells, dendritic cells (DCs) and macrophages and its expression is up-regulated during inflammation. Secreted form of Opn (s-Opn), which is modified by phosphorylation, glycosylation and proteolytic cleavage with thrombin, has activities as a T helper type 1 (Th1) cytokine and as a chemoattractant for many types of cells through integrin receptors and CD44. Recently, it has been uncovered that intracellular form of Opn (i-Opn) is a critical regulator for Toll like receptor-9 (TLR-9), TLR-7- dependent interferon-α (IFN-α) expression by plasmacytoid DCs and Th17 development. In this review, we have summarized recent progress in understanding of Opns role in variety of inflammatory disorders.
Export Options
About this article
Cite this article as:
Morimoto Junko, Kon Shigeyuki, Matsui Yutaka and Uede Toshimitsu, Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases, Current Drug Targets 2010; 11 (4) . https://dx.doi.org/10.2174/138945010790980321
DOI https://dx.doi.org/10.2174/138945010790980321 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades
Current Pharmaceutical Design Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Current Pharmaceutical Design A Review on the Techniques for Characterizing and Predicting Human Genomic DNA Methylation
Current Bioinformatics ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Bridging Indigenous Knowledge and Scientific Evidence for Pharmacological Studies of <i>Phaleria macrocarpa</i>: A Systematic Review
The Natural Products Journal Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research IRAK-4 Inhibitors for Inflammation
Current Topics in Medicinal Chemistry Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design New Aspects of Integrin-mediated Leukocyte Adhesion in Inflammation: Regulation by Haemostatic Factors and Bacterial Products
Current Molecular Medicine An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region
Current Rheumatology Reviews Recent Development and Future Prospects of Plant-Based Vaccines
Current Drug Metabolism NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Concept of Comprehensive Treatment for Osteoarthritis (OA)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Proteins Structures in Leishmania Amastigotes for Clinical Remission of Psoriasis
Current Proteomics The Design, Synthesis and Application of Stereochemical and Directional Peptide Isomers: A Critical Review
Current Protein & Peptide Science Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Drug Targets in Infections with Ebola and Marburg Viruses
Infectious Disorders - Drug Targets